Vascular access outcomes reported in maintenance hemodialysis trials : a systematic review by Viecelli, Andrea K et al.
Original InvestigationVascular Access Outcomes Reported in Maintenance
Hemodialysis Trials: A Systematic Review
Andrea K. Viecelli, Emma O’Lone, Benedicte Sautenet, Jonathan C. Craig, Allison Tong, Eric Chemla,
Lai-Seong Hooi, Timmy Lee, Charmaine Lok, Kevan R. Polkinghorne, Robert R. Quinn, Tushar Vachharajani,
Raymond Vanholder, Li Zuo, Ashley B. Irish, Trevor A. Mori, Elaine M. Pascoe, David W. Johnson, and
Carmel M. HawleyComplete author and article
information provided before
references.
Correspondence to
A.K. Viecelli (andrea.
viecelli@health.qld.gov.au)
Am J Kidney Dis. 71(3):
382-391. Published online
December 1, 2017.
doi: 10.1053/
j.ajkd.2017.09.018
© 2017 by the National
Kidney Foundation, Inc.
Published by Elsevier Inc.
All rights reserved.
3Background: Many randomized controlled trials
have been performed with the goal of improving
outcomes related to hemodialysis vascular access.
If the reported outcomes are relevant and
measured consistently to allow comparison of in-
terventions across trials, such trials can inform de-
cision making. This study aimed to assess the
scope and consistency of vascular access out-
comes reported in contemporary hemodialysis
trials.
Study Design: Systematic review.
Setting & Population: Adults requiring mainte-
nance hemodialysis.
Selection Criteria: All randomized controlled tri-
als and trial protocols reporting vascular access
outcomes identiﬁed from ClinicalTrials.gov,
Embase, MEDLINE, and the Cochrane Kidney
and Transplant Specialized Register from January
2011 to June 2016.
Interventions:Any hemodialysis-related intervention.
Outcomes: The frequency and characteristics of
vascular access outcome measures were
analyzed and classiﬁed.
Results: From 168 relevant trials, 1,426 access-
related outcome measures were extracted and
classiﬁed into 23 different outcomes. The 382most common outcomes were function (136
[81%] trials), infection (63 [38%]), and
maturation (31 [18%]). Function was measured
in 489 different ways, but most frequently
reported as “mean access blood ﬂow (mL/min)”
(37 [27%] trials) and “number of thromboses”
(30 [22%]). Infection was assessed in 136
different ways, with “number of access-related
infections” being the most common measure.
Maturation was assessed in 44 different ways
at 15 different time points and most commonly
characterized by vein diameter and blood ﬂow.
Patient-reported outcomes, including pain (19
[11%]) and quality of life (5 [3%]), were
reported infrequently. Only a minority of trials
used previously standardized outcome
deﬁnitions.
Limitations: Restricted sampling frame for
feasibility and focus on contemporary trials.
Conclusions: The reporting of access outcomes
in hemodialysis trials is very heterogeneous, with
limited patient-reported outcomes and infrequent
use of standardized outcome measures. Efforts
to standardize outcome reporting for vascular
access are critical to optimizing the
comparability, reliability, and value of trial
evidence to improve outcomes for patients
requiring hemodialysis.A reliably functioning vascular access is associated withimproved health outcomes and overall well-being of
patients treated by maintenance hemodialysis, but estab-
lishing and maintaining such a vascular access without
major complications and the need for recurrent in-
terventions remains challenging.1-3 Vascular access–related
complications account forw20% of hospital admissions of
patients with end-stage kidney disease annually and are
associated with increased morbidity, mortality, and health
care costs.4,5 As such, vascular access is often referred to as
both the “lifeline” and “Achilles’ heel” of hemodialysis.6
From a patient’s perspective, the experience and anticipa-
tion of vascular access surgery and complications, partic-
ularly pain during cannulation, bleeding, and access
failure, are key sources of stress and anxiety.7,8 Improving
vascular access outcomes is a high priority for patients,
their caregivers, and health professionals.9,10
During the last 2 decades, numerous interventions have
been trialed in an attempt to improve vascular accessoutcomes, with little success.11-13 This is in the context of
increasing recognition across many health conditions that
outcomes used in clinical trials are measured inconsistently
and may not be relevant to end-users, including patients,
caregivers, and health professionals.2,7,8,14,15 In addition,
reporting bias due to selective publication of outcomes
with favorable results makes interpretation and compari-
son of research output unreliable.16,17 The lack of
consensus on outcome selection (ie, what to measure, such
as “infection” or “pain”) and outcome measures (ie, how
and when to measure the outcome, such as “number of
access interventions within 12 months of access creation”)
has been identified as an additional source of research
waste.18-21 The comparability, value, and reliability of trial
evidence are compromised by the selection of outcomes
with limited clinical or policy relevance, under-reporting
of patient-centered outcomes, and inconsistent use of
outcome measures. There have been efforts to standardize
outcome definitions for vascular access by various workingAJKD Vol 71 | Iss 3 | March 2018
Original Investigationgroups, with the most recent publication released in
2011.22-25 However, these may not have been widely
adopted.
This study aimed to describe the scope and consistency
of vascular access outcomes and outcome measures used in
contemporary hemodialysis trials and assess the use of
previously published standardized outcome definitions. A
secondary longer-term aim is to underpin strategies to
prioritize outcomes, improve outcome reporting for
vascular access complications, increase the value of future
trials to inform evidence-based practice, and ultimately,
help improve patient outcomes.Methods
Selection Criteria
An electronic search using Embase, the Cochrane Kidney
and Transplant Specialized Register, and MEDLINE data-
bases without language restriction was conducted using
search strategies developed in collaboration with a
specialist information manager to identify trials reporting
on vascular access outcomes in adult (aged ≥ 18 years)Figure 1. Search results. aEstimated number of enrollment. bSamp
AJKD Vol 71 | Iss 3 | March 2018patients requiring maintenance hemodialysis (Table S1).
Trials in patients with acute kidney injury undergoing
temporary hemodialysis were excluded. All randomized
controlled trials including protocols and post hoc analyses
of randomized controlled trials published between January
1, 2011, and June 16, 2016, were included. This time
frame was chosen to provide an assessment of contem-
porary outcome measures of recently published and
ongoing trials allowing for implementation of previously
published standardized outcome measures.22-25 Systematic
reviews and meta-analyses were screened to identify
additional randomized controlled trials published within
the same time frame. In addition, the ClinicalTrials.gov
registry was searched for unpublished protocols of ran-
domized controlled trials using the same inclusion criteria
to ensure that current and ongoing trials were included.
Trials of registered protocols that had completed recruit-
ment before January 2011; terminated recruitment due to
poor enrollment; been withdrawn, suspended, or pub-
lished; or not yet started recruitment were excluded.
Research ethics committee approval was not required for
this study.le size unknown in 4 trials.
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Table 1. Characteristics of Included Trials
Trial Characteristic No. of Trials
Year of publication
2011-2012 45 (27%)
2013-2014 45 (27%)
2015-2016 23 (14%)
Unpublished (ongoing or completed trial) 55 (33%)
Country
Not stated/not reporteda 55 (33%)
United States 17 (10%)
Iran 17 (10%)
Canada 10 (6%)
United Kingdom 8 (5%)
Taiwan 7 (4%)
Italy 6 (4%)
Turkey 5 (3%)
Greece 4 (2%)
Spain 4 (2%)
Australia 3 (2%)
China 3 (2%)
Multinational studies 10 (6%)
Otherb 19 (11%)
Sample sizec
1-50 35 (21%)
51-100 54 (32%)
101-150 22 (13%)
151-200 15 (9%)
>200 38 (23%)
Not reported 4 (2%)
Duration of trial, mo
≤3 40 (24%)
>3-6 32 (19%)
>6-9 2 (1%)
>9-12 48 (29%)
>12 37 (22%)
Not reported 9 (5%)
Intervention type
Pharmacologic 79 (47%)
Radiologic 11 (7%)
Catheter type 11 (7%)
Surgical 9 (5%)
Radiologic/pharmacologic combined 9 (5%)
Graft material 7 (4%)
Anesthetic 7 (4%)
Cannulation technique 7 (4%)
Dialysis delivery 5 (3%)
Radiation 5 (3%)
Exercise 3 (2%)
Otherd 15 (9%)
No. of outcome measures reported in each trial
1-5 97 (58%)
6-10 31 (18%)
11-15 23 (14%)
>16 17 (10%)
Access type
AVF 69 (41%)
CVC 53 (32%)
(Continued)
Table 1 (Cont'd). Characteristics of Included Trials
Trial Characteristic No. of Trials
AVG 17 (10%)
All 14 (8%)
AVF and AVG 14 (8%)
CVC and AVF 1 (1%)
Note: n = 168. Values are given as count (percentage).
Abbreviations: AVF, arteriovenous ﬁstula; AVG, arteriovenous graft; CVC, central
venous catheter.
aTrials only registered with ClinicalTrial.gov did not report countries (n=55).
bAsia (n = 1), Belgium (n = 2), Brazil (n = 1), Egypt (n = 1), France (n = 1), Georgia
(n = 1), Germany (n = 2), India (n = 1), Israel (n = 1), Japan (n = 2), Korea (n = 1),
Pakistan (n = 1), Poland (n = 2), and United Arab Emirates (n=2).
cIncluding estimated numbers for trial protocols according to latest update on
ClinicalTrials.gov (June 2016).
dAccess location (n = 2), access planning (n = 1), algorithm (n = 3), behavioral
(n = 2), biological (n = 1), education (n = 1), surgical/interventional combined
(n = 1), surveillance (n = 1), and ultrasound (n = 3).
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For each trial, one reviewer (AV) extracted the following
trial characteristics if available: first author, year of publi-
cation (for published trials) and year of registration with
ClinicalTrials.gov (for unpublished trials), participating
countries, sample size, study duration, intervention type,
access type, and all vascular access–related outcomes. All
levels of specification of outcome measures were collected
if reported by 1 reviewer (AV): outcome (eg, infection or
cannulation problems), specific measurement (eg,
catheter-related bacteremia or successful cannulation at
first attempt), specific metric (ie, time to event, change
from baseline, or milliliters per minute), method of ag-
gregation (ie, mean, median, or proportion), and time
point of measurement in line with previously published
tools.19,26
Analysis
Two reviewers independently grouped individual outcome
measures assessing a similar aspect of vascular access
complications into outcomes. Discrepancies were dis-
cussed to reach agreement (AV and BS). The list of out-
comes was reviewed and agreed on by 4 additional
reviewers (AT, CH, EO, and JC). Reviewer AV assigned all
outcomes to 3 categories based on the majority of outcome
measures: clinical (a “direct” medical end point based on
clinician assessment or diagnosis that in itself represents or
characterizes a meaningful outcome), surrogate (a labo-
ratory, imaging-based, or physical sign that is used as a
substitute for a clinically meaningful end point), and
patient-reported (outcomes reported by the patients usu-
ally relating to quality of life or symptoms) using standard
definitions.27,28 The classification was agreed on by 2 re-
viewers (AT and JC).Results
Trial Characteristics
We identified 168 relevant trials involving 29,038 par-
ticipants (Fig 1). Two-thirds of trials were published
and one-third were registered trial protocols (Table 1).AJKD Vol 71 | Iss 3 | March 2018
Figure 2. Percentage of trials reporting each vascular access outcome (total 168 trials, 23 outcomes). Outcome categories: clinical
(black), patient-reported (grey), and surrogate (white). Outcomes reported in <2% of trials: venous hypertension (surrogate),
procedure-related complications (clinical), patient satisfaction (patient-reported), erythema (clinical), needle phobia/fear (patient-
reported), vascular access location (surrogate), and inﬂammation (surrogate).
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outcomes.
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=Original InvestigationPublished trials were conducted across 39 countries
from North America, Latin America, Europe, Middle
East, Asia, and Oceania. Median trial duration was 12
(interquartile range [IQR], 6-24) months, and median
sample size was 96 (IQR, 61-196) participants. The
most commonly studied type of intervention was
pharmacologic (47%). Forty-one percent of trials
investigated vascular access outcomes in arteriovenous
fistulas alone; 32%, in central venous catheters; 10%, in
arteriovenous grafts; and 17% of studies included
various combinations of access types.
Outcomes
In total, 1,426 outcome measures were identified
(defined by the measurement, metric, method of ag-
gregation, and time point of measurement), which
could be grouped into 23 outcomes, of which 15 (65%)
were predominantly clinical, 4 (17%) were surrogate,
and 4 (17%) were patient-reported. The 3 most frequent
outcomes were function (136 [81%] trials), infection
(63 [38%] trials), and maturation (31 [18%] trials).
Pain was the most common patient-reported outcome
and was assessed in 19 (11%) trials. Less than 5% of
trials reported quality of life (5 [3%] trials), satisfaction
with the vascular access (2 [1%]), or needle phobia (1
[<1%]). Nineteen (11%) trials measured vessel charac-
teristics, which was the most commonly reported sur-
rogate outcome (Fig 2).
Outcome Measures
The number of outcome measures of the 10 most
frequently reported specified vascular access outcomes are
presented in Figure 3.
Function
Function was measured in 489 different ways and at 46
different time points. Function was the most heteroge-
neous outcome due to the variety of ways it can be
assessed (Fig S1). The most frequently used outcomeFigure 4 (previous page). (A) Most frequently reported outcome
function (136 trials, 23 of 489 outcome measures). The proportion
time points the outcome measure has been reported at (dots). Deﬁn
of Interventional Radiology (SIR)24: interval following intervention u
patency as deﬁned by the Society of Vascular Surgery (SVS) and
interval from the time of access placement until any intervention d
or the time of measurement of patency. (B) Most frequently repor
infection (63 trials, 15 of 136 outcomes measures). The proportion
time points the outcome measure has been reported at (dots). D
criteria31,32: bacteremia/fungemia in a patient with an intravascular c
ripheral vein, clinical manifestations of infections (ie, fever, chills, an
infection except the catheter. Deﬁnite bloodstream infection: isola
catheter-derived blood sample of a symptomatic patient (fever, chill
able source of infection. Probable bloodstream infection: infectiou
cultures or culture of the catheter tip, but not both, conﬁrm infectio
source of infection. Possible bloodstream infection: disappearance
blood and catheter tip cultures after catheter removal when there
AJKD Vol 71 | Iss 3 | March 2018measures for assessing the function of a vascular access
included mean access blood flow in milliliters per minute
(37 trials [27%]) and number of thromboses (30 trials
[22%]; Fig 4A). Approximately one-third of outcome
measures described patency, thrombosis, or stenosis (Fig
S1). Of the 134 patency measures reported across 64 tri-
als, 17 (13%) were consistent with 1 or more of the
patency definitions as proposed by the Society for Vascular
Surgery and the American Association for Vascular Sur-
gery, the Society of Interventional Radiology Technology
Assessment, or the North American and Australian Vascular
Access Consortium.22-24
Infection
Infection was reported in 136 different ways (not including
variation in time points) and at 20 different time points,
with 30 (22%) consistent with criteria used by the US
Centers for Disease Control and Prevention (CDC) and/or
other published definitions.29-32 Number of access-related
infections was the most commonly used outcome mea-
sure (10% of trials; Fig 4B). Ninety different outcome
measures were used to assess catheter-related infections
(excluding time points), of which 64 referred specifically to
systemic catheter-related infection; 11, to exit-site infec-
tion; and 4, to tunnel infection. The rate (number per 1,000
catheter-days) and type (causative organism) of catheter-
related bloodstream infection, as defined by the CDC,32
were the most frequently used catheter-related outcome
measures, and each was reported in only 8% of trials.
Maturation
Maturation was measured in 43 different ways and at 15
different time points (Fig S2), with one-quarter of trials
referring to previously published criteria.29,33 Maturation
was most commonly defined as number of fistulas with a
vein diameter of 6 mm and blood flow > 600 mL/min29
and/or vein diameter of 4 mm and blood flow of at least
500 mL/min33 or as time to first cannulation (n = 2 [6%]
trials for each outcome measure).measures (deﬁnitions and time points) to assess vascular access
of trials reporting each outcome measure (bars) and the different
itions: Postintervention primary patency as deﬁned by the Society
ntil the next access thrombosis or repeated intervention. Primary
American Association for Vascular Surgery (AAVS) 200223: the
esigned to maintain or re-establish patency, access thrombosis,
ted outcomes measures (deﬁnitions and time points) to assess
of trials reporting each outcome measure (bars) and the different
eﬁnitions: Centers for Disease Control and Prevention (CDC)
atheter with at least 1 positive blood culture obtained from a pe-
d/or hypotension), and no apparent source for the bloodstream
tion of the same organism from a peripheral-blood sample and
s, hypotension, or mental confusion) when there is no other prob-
s symptoms disappear after catheter removal when either blood
n in a symptomatic patient in the absence of another suspicious
of infectious symptoms in a symptomatic patient with negative
is no other probable source of infection.45
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The patient-reported outcome pain was assessed in 19
trials using 29 different outcome measures. Two (10%)
studies measured procedural pain, but the majority of
studies (n = 15 [79%]) assessed pain during cannulation
using 1 of 11 different methods to quantify pain (Fig S3).
Bleeding/Hematoma
Access-related hematomas or the occurrence of bleeding
from the access site were recorded in 26 trials and
measured in 29 different ways at 24 different time points
(Fig S4). Number of hematomas was the most frequently
used outcome measure and was recorded by more than a
quarter of trials (n = 7), followed by number of access-
related bleeding episodes (n = 4 [15%]). Bleeding after
removal of dialysis needles was assessed in 7 different
ways, including bleeding time, number or proportion of
bleeding episodes following removal of the dialysis nee-
dles, and number of prolonged bleeding episodes (defined
as >10 minutes’ duration or unspecified).
The surrogate outcome, vessel characteristics, included
measurements of vessel diameter, depth, and wall thick-
ness and was evaluated in 26 different ways (Fig S5).
Outcome measures for cannulation problems, steal syn-
drome, aneurysms, and vascular access–related hospitali-
zation provided in Figures S6 to S9 were heterogeneous,
as highlighted by the fact that the majority of outcome
measures were only used in 1 or 2 trials.Discussion
The vascular access outcomes reported in clinical trials of
adult patients requiring hemodialysis were most frequently
clinical, such as function, infection, and maturation.
Patient-reported outcomes, including pain, quality of life,
satisfaction with the vascular access, and fear of cannula-
tion, were rarely reported. The outcome measures used
were extremely numerous and heterogeneous at every
level; measurement, metric, method of aggregation, and
time point of measurement, making it very difficult to
reliably evaluate the comparative effectiveness of different
interventions designed to improve the lives of people
receiving hemodialysis. Attempts to standardize definitions
appear to have been only partially successful, with a mi-
nority of trials using such definitions.
This study highlights the plethora and broad hetero-
geneity of vascular access outcome measures across trials in
hemodialysis, with 1,426 outcome measures used to assess
23 different outcomes. This inconsistency was observed at
all levels of an outcome measure.26 Consequently,
comparative assessments of vascular access outcomes
across trials to guide evidence-based clinical practice (ie,
meta-analyses) are likely to be problematic. The need for
standardizing outcome measures for vascular access com-
plications has been recognized and several proposals have
been published by expert committees and societies over
the past 2 decades.22-24,30-32,34 However, as demonstrated388in this study, implementation of standardized outcome
measures into recent clinical trials and trial protocols is
infrequent. Major barriers to global implementation of
standardized outcome measures may be the limited
engagement of stakeholders from all relevant clinical spe-
cialties (ie, vascular access surgery, interventional radi-
ology, and nephrology), different types of health
professionals (eg, nurses and physicians), regulatory
bodies and policy makers, and patients. Feasibility and
relevance may also be issues, with selected outcome
measures being cumbersome to collect and regarded as of
limited clinical utility for daily practice and quality
improvement.
A potential strategy to overcome these barriers may
be the implementation of a “core outcome set” incor-
porating a consensus-based “minimum set of outcomes
that should be measured and reported in all clinical trials
of a specific disease or trial population.”18(p. 2) This
would ensure that results can be compared across trials
and that all trials contribute relevant and usable infor-
mation.18 The Outcome Measures in Rheumatology
(OMERACT) initiative was the first to establish core
outcomes for clinical trials and has led to improvements
in the reporting and relevance of outcomes in rheu-
matology.35 A recent analysis demonstrated that
reporting and homogeneity of outcomes were better in
registered trial protocols for rheumatology compared to
those for nephrology.19 There have been increasing ef-
forts to identify and establish core outcomes in
nephrology, as evident from recent work via the Stan-
dardized Outcomes in Nephrology (SONG) initia-
tive.10,36,37 Based on the shared priorities of patients
and their caregivers, clinicians, researchers, and policy
makers, vascular access has been identified as a core
outcome domain in hemodialysis. This study, led by
the SONG Hemodialysis Vascular Access Expert
Working Group,38 further informs the process of
establishing and implementing a core outcome measure
for vascular access that is: (1) considered important and
relevant by all relevant stakeholders, (2) feasible across
different clinical settings without adding additional
burden to clinicians or patients, (3) inexpensive, and
(4) relevant to clinical decision making and quality
improvement.
Function was the most commonly reported vascular
access outcome in hemodialysis trials. Although throm-
bosis and access flow were the most frequently used
outcome measures to assess function, these outcomes
may not capture all relevant contributing aspects of
function and dysfunction of a vascular access and may
therefore lack content validity.18 For example, using
thromboses as an outcome measure may not adequately
assess whether an intervention improves the function and
usability of a vascular access. Results from the largest
interventional vascular access trial to date showed that
despite clopidogrel leading to a reduction in early
thrombosis rates, this did not translate into aAJKD Vol 71 | Iss 3 | March 2018
Original Investigationsimultaneous improvement in the usability of fistulas for
hemodialysis,39 suggesting that other unmeasured out-
comes may play a greater role.
There is increasing interest in using outcome measures
considered important by patients. This study showed that
patient-reported vascular access problems were measured
infrequently in hemodialysis trials and therefore the effect
of many interventions on patients’ comfort and satisfac-
tion with their vascular accesses remains uncertain. Pain
during cannulation has been identified as the most
commonly reported problem by patients,8 yet was
assessed in only 11% of trials. Cosmetic and lifestyle
considerations such as restrictions on showering and
swimming with a catheter, free time lost to frequent ap-
pointments for access procedures, and fear of a potentially
life-threatening hemorrhage of an aneurysmal access are
also important to patients, but these outcomes were not
reported in any of the studies included in our systematic
review.7,40
This study addresses an evidence gap by providing a
detailed analysis of the scope and consistency of vascular
access outcome measures and of the implementation of
previously published standardized outcome definitions
across a large selection of contemporary hemodialysis tri-
als. Limitations of this study include the sampling frame
that was restricted to recently published (since January
2011) and ongoing trials, which may have introduced
selection bias. However, attempts were made to provide a
contemporary assessment of outcomes and outcome
measures and assess the use of previously published
outcome definitions with the most recent publication
released in 2011.22 It is likely that including older trials
would only have increased the heterogeneity of outcome
measures due to less consistency with existing outcome
definitions, only strengthening the study’s key findings.
The quality or risk of bias of included trials was not
assessed, such that it was not possible to evaluate the as-
sociation between the reliability of trial results and the
outcomes reported.
In conclusion, there is substantial variability and
inconsistency in vascular access outcomes and outcome
measures reported in hemodialysis trials, with very little
focus on patient-reported outcomes, making it difficult for
clinicians, patients, and policy makers to make informed
decisions. Clinicians are encouraged to judge current trial
outcomes and measures based on the relevance to their
patients and clinical practice. To improve the relevance and
consistency of vascular access outcome measures used in
clinical trials and day-to-day clinical practice, we recom-
mend implementation of trial end points tailored to the
different types of vascular access and time points of their
life cycle. These were recently published by the Dialysis
Vascular Access group of the American Society of
Nephrology Kidney Health Initiative.41-43 Complementing
the Kidney Health Initiative, the international SONG
initiative has established a core outcome set for hemodi-
alysis that includes vascular access as 1 of 4 core outcomeAJKD Vol 71 | Iss 3 | March 2018domains based on the shared priorities of patients and
health professionals.10,36,44
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